Li Zhihua, Hu Feng, Li Qian, Wang Shuang, Chen Chunli, Zhang Yongpeng, Mao Yu, Shi Xuehui, Zhou Haiying, Cao Xusheng, Peng Xiaoyan
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 17 Hougou Lane, Chongnei Street, Beijing 100005, China.
Beijing Institute of Ophthalmology, Beijing 100005, China.
Vaccines (Basel). 2022 Jun 9;10(6):918. doi: 10.3390/vaccines10060918.
Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8−71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary.
报告在中国接种新型冠状病毒灭活疫苗后发生的眼部不良事件的临床特征。方法：对在接种任何一剂新型冠状病毒灭活疫苗后15天内发生的眼部疾病进行回顾性横断面观察研究。回顾性收集性别、年龄、接种疫苗与眼部症状出现的间隔时间、患侧、眼部症状持续时间、初始视力和临床诊断等信息。结果：24例患者参与研究，其中女性15例，男性9例，平均年龄41±16岁（8至71岁）。所有患者均否认有新型冠状病毒感染病史。18例患者在接种第一剂疫苗后出现眼部不良事件，6例患者在接种第二剂或第三剂后出现。接种新型冠状病毒灭活疫苗与眼部症状出现的间隔时间为6±5天；6例患者双眼受累，18例患者单眼受累。诊断方面，10例患者被诊断为白点综合征（WDS），9例患者被诊断为葡萄膜炎，5例患者被诊断为视网膜血管疾病。WDS患者的年龄比葡萄膜炎或视网膜血管疾病患者年轻（32±10岁对48±18岁，p<0.05）。对于诊断为WDS的患者，最佳矫正视力（BCVA）为0.74±0.73 LogMAR。对于诊断为视网膜血管疾病或葡萄膜炎的患者，BCVA为1.44±1.26 LogMAR。差异无统计学意义（p>0.05）。结论：无法确定新型冠状病毒灭活疫苗与眼部疾病之间存在关联；因此，有必要进一步研究接种新型冠状病毒灭活疫苗后眼部不良事件的临床谱。
